Preventing Hepatitis B Reactivation During Anti‐CD20 Antibody Treatment in the Veterans Health Administration

Hepatitis B virus (HBV) reactivation may occur with high risk immunosuppression, such as anti‐cluster of differentiation (CD)20 antibodies (Abs). Appropriate HBV prophylaxis during anti‐CD20 Ab therapy averts hepatitis, chemotherapy disruption, and death. Serologic evidence of prior HBV exposure is...

Descripción completa

Detalles Bibliográficos
Autores principales: Jasmine Bullard, A., Cunningham, Francesca E., Volpp, Bryan D., Lowy, Elliott, Beste, Lauren A., Heron, Bernadette B., Geraci, Mark, Hammond, Julia M., LaPlant, Kourtney, Stave, Elise A., Turner, Marsha J., O’Leary, Meghan C., Kelley, Michael J., Hunt, Christine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128236/
https://www.ncbi.nlm.nih.gov/pubmed/30202826
http://dx.doi.org/10.1002/hep4.1238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128236/
https://www.ncbi.nlm.nih.gov/pubmed/30202826
http://dx.doi.org/10.1002/hep4.1238

Ejemplares similares